[en] Two clinical trials demonstrate the superiority versus a placebo of two antidiabetic drugs in patients with type 2 diabetes and high cardiovascular risk. Empagliflozin, an inhibitor of sodium-glucose type 2 (SGLT2) cotransporters, in EMPA-REG OUTCOME, and liraglutide, an agonist of glucagon-like peptide-1 (GLP-1) receptors, in LEADER, showed a significant reduction in major cardiovascular events (- 14 and - 13 %, respectively), cardiovascular mortality (- 38 and - 22 %, respectively) and all-cause mortality (- 32 and - 15 %, respectively). A lower progression of kidney disease and less renal events were also reported. The underlying protective mechanisms remain controverted as the discussion whether the benefits are specific to each medication or could be extended to other molecules of these two pharmacological classes.
Scheen, André ; Université de Liège > Département des sciences cliniques > Département des sciences cliniques
WALLEMACQ, Caroline ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de diabétologie, nutrition, maladies métaboliques
Jandrain, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de diabétologie, nutrition, maladies métaboliques
Ernest, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Autres Services Médicaux > Pharmacologie clinique
Language :
French
Title :
Protection cardiovasculaire du patient diabetique de type 2 : d'EMPA-REG OUTCOME a LEADER.
Alternative titles :
[en] Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER
Scheen AJ. Editorial: Que penser de tous ces essais de non-infériorité pour démontrer la sécurité cardiovasculaire des nouveaux médicaments antidiabétiques? Rev Med Suisse 2015;11:1515-6.
Ryden L, Shahim B, Mellbin L. Clinical implications of cardiovascular outcome trials in type 2 diabetes: From DCCT to EMPA-R EG. Clin Ther 2016;38:1279-87.
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26.
White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35.
Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-42.
Scheen AJ. Gliptines, sécurité cardiovasculaire et insuffisance cardiaque: le point après l'étude TECO S. Rev Med Suisse 2015;11:1526-31.
Scheen AJ, Charbonnel B. Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal. Diabetes Metab 2014;40: 176-85.
OR IGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-28.
Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-57.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016 ; epub ahead of print.
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016 ; epub ahead of print.
Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCO ME). Cardiovasc Diabetol 2014;13:102.
Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: Results of the EMPA-R EG OUTCO ME trial. Eur Heart J 2016;37:1526-34.
Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015;75:33-59.
Scheen AJ. SGLT2 inhibition: Efficacy and safety in type 2 diabetes treatment. Exp Opin Drug Safety 2015;14:1879-904.
Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 2016 ; epub ahead of print.
Marso SP, Poulter NR, Nissen SE, et al. Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J 2013;166:823-30 e5.
Masmiquel L, Leiter LA, Vidal J, et al. LEADER 5: Prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: Baseline global data from the LEADER trial. Cardiovasc Diabetol 2016;15:29.
Petrie JR, Marso SP, Bain SC, et al. LEADER-4: Blood pressure control in patients with type 2 diabetes and high cardiovascular risk: Baseline data from the LEADER randomized trial. J Hypertens 2016;34:1140-50.
Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 2015;12:90-100.
Scheen AJ. Reduction in cardiovascular and all-cause mortality in the EMPA-R EG OUTCO ME trial: A critical analysis. Diabetes Metab 2016;42:71-6.
DeFronzo RA. The EMPA-R EG study: What has it told us? A diabetologist's perspective. J Diabetes Complications 2016;30:1-2.
Sattar N, McLaren J, Kristensen SL, et al. SGLT2 inhibition and cardiovascular events: Why did EMPA-R EG outcomes surprise and what were the likely mechanisms? Diabetologia 2016;59:1333-9.
Abdul-Ghani M, Del Prato S, Chilton R, et al. SGLT2 inhibitors and cardiovascular risk: Lessons learned from the EMPA-R EG OUTCO ME study. Diabetes Care 2016;39:717-25.
Marx N, McGuire DK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J 2016 ; epub ahead of print.
Scheen AJ. Reappraisal of the diuretic effect of empagliflozin in EMPA-R EG OUTCO ME: Comparison with classic diuretics. Diabetes Metab 2016;42:S1262-3636(16)30409-8.
Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrates utilization in response to sodium-glucose co-transporter-2 inhibition in nondiabetic subjects and type 2 diabetic patients. Diabetes 2016;65:1190-5.
Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-R EG OUTCO ME study? A unifying hypothesis. Diabetes Care 2016;39: 1115-22.
De Flines J, Scheen AJ. Glitazones et insuffisance cardiaque: résultats des études PRO active, ADOPT, DREAM et RECORD. Rev Med Suisse 2007;3:1876-83.
Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH. EMPA-R EG and other cardiovascular outcome trials of glucose-lowering agents: Implications for future treatment strategies in type 2 diabetes mellitus. Clin Ther 2016;38: 1288-98.
Scheen AJ. Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonists. Lancet Diabetes Endocrinol 2015;3:667-9.
Nauck M, Rizzo M, Johnson A, et al. Once-daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: A 26-week randomized controlled clinical trial. Diabetes Care 2016 ; epub ahead of print.
Scheen AJ, Paquot N. Combinaison gliptine-gliflozine dans le traitement du diabète de type 2 Rev Med Suisse 2016;12:1384-8.
